{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T15:34:00Z","timestamp":1776008040895,"version":"3.50.1"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Results are consistent with MBC-11 targeting and treating cancer-induced bone lesions by concentrating cytarabine and etidronate at the site of disease. MBC-11 was well tolerated, with an maximum tolerated dose of 5 mg\/kg per day and myelosuppression as the principal toxicity. Treatment significantly reduced cancer cell activity in over half of bone lesions detected at baseline. MBC-11 pharmacokinetic and pharmacodynamic parameters are consistent with the novel drug design goals, and encouraging results warrant further clinical development.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). This first-in-human phase I dose escalation study assessed safety, tolerability, maximum tolerated dose (MTD), plasma pharmacokinetics, bone turnover, tumor biomarkers, and bone lesion activity by fluorodeoxyglucose positron emission tomography\/computed tomography (18F-FDG-PET\/CT) imaging.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Fifteen patients with advanced solid cancers and cancer-induced bone disease (CIBD) were treated with 0.5\u201310 mg\/kg per day of MBC-11 administered daily for 5 days of every 4 weeks for up to four cycles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Grade 1\u20132 myelosuppression, involving all lineages, was the principal toxicity. Two of three patients treated with 10 mg\/kg experienced dose-limiting grade 4 neutropenia and thrombocytopenia (adverse event [AE] duration \u22645 days); the MTD was 5 mg\/kg. Four of five patients with pretreatment elevations of the bone resorption marker TRAP5b (tartrate resistant acid phosphatase-5b) had persistent decrements. Six of 13 patients who reported baseline pain noted a reduction after MBC-11. 18F-FDG-PET\/CT imaging demonstrated partial metabolic responses in three patients and stable metabolic responses in three other patients. SUVmax (standard unit of emission normalized to total uptake) was reduced by at least 25% in 110 (52%) of 211 bone lesions. Significant activity was noted across all doses, and myelosuppression increased with dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>At MBC-11 doses that were well tolerated, substantial reductions in metabolic activity of bone-associated cancer cells provide a foundation for further disease-directed efficacy studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0707","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T15:45:41Z","timestamp":1541778341000},"page":"303-e102","source":"Crossref","is-referenced-by-count":17,"title":["First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease"],"prefix":"10.1093","volume":"24","author":[{"given":"Shawn Patrick","family":"Zinnen","sequence":"first","affiliation":[{"name":"MBC Pharma Inc., Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Karpeisky","sequence":"additional","affiliation":[{"name":"MBC Pharma Inc., Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[{"name":"Translational Genomics Research Institute (TGEN), Phoenix, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Plekhova","sequence":"additional","affiliation":[{"name":"Osteros Biomedica Ltd., Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Alexandrov","sequence":"additional","affiliation":[{"name":"Maxwell Biotech Group, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"2021122506315470800_onco12741-bib-0001","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1021\/jo800317e","article-title":"Bisphosphonate derivatives of nucleoside antimetabolites: Hydrolytic stability and hydroxyapatite adsorption of 5'-beta, gamma-methylene and 5'-beta, gamma-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidine","volume":"73","author":"Ora","year":"2018","journal-title":"J Org Chem"},{"key":"2021122506315470800_onco12741-bib-0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bone.2010.03.006","article-title":"A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites","volume":"47","author":"Reinholz","year":"2010","journal-title":"Bone"},{"issue":"suppl 1","key":"2021122506315470800_onco12741-bib-0003","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"2021122506315470800_onco12741-bib-0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"2021122506315470800_onco12741-bib-0005","volume-title":"Didronel (etidronate disodium) [package insert]","year":"2009"},{"key":"2021122506315470800_onco12741-bib-0006","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/10428199709059686","article-title":"Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal","volume":"27","author":"Burk","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"2021122506315470800_onco12741-bib-0007","first-page":"54","article-title":"Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine","volume":"28","author":"Capizzi","year":"1991","journal-title":"Semin Hematol"},{"key":"2021122506315470800_onco12741-bib-0008","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.bone.2010.10.145","article-title":"Evaluation of a novel bone targeted aracytidine therapy in dogs with spontaneous osteosarcoma","volume":"48","author":"Zinnen","year":"2011","journal-title":"Bone"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0707","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0707","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/3\/303\/41917164\/oncolo_24_3_303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/3\/303\/41917164\/oncolo_24_3_303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:32:08Z","timestamp":1640413928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/3\/303\/6439149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":8,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,11,9]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0707","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,1]]},"published":{"date-parts":[[2018,11,9]]}}}